Lexaria Bioscience Stock Forum

$Lexaria Bioscience (LEXX.US)$
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Lexaria Bioscience Corp. (NASDAQ:LEXX) announces final 12-week results from its diabetes animal study WEIGHT-A24-1. All groups using DehydraTECH technology outperformed Rybelsus® in body weight control. DehydraTECH-liraglutide and DehydraTECH-CBD were top performers, surpassing Rybelsus® control group in body weight-loss b...

$Lexaria Bioscience (LEXX.US)$
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

$Lexaria Bioscience (LEXX.US)$
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced positive results from its second GLP-1 human pilot study (GLP-1-H24-2) on DehydraTECH-processed Rybelsus® oral capsules. Key findings include:
1. Superior tolerability: None of the 9 participants taking DehydraTECH-processed Rybelsus® capsules experienced adverse events, compared...

Strong move today. If 4.11 holds watch for a push to 4.44. Here are the levels to watch today.
Larger Image: tradingview.com...
$Lexaria Bioscience (LEXX.US)$  

$Lexaria Bioscience (LEXX.US)$ Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events
MT Newswires· 1 min ago

$Lexaria Bioscience (LEXX.US)$ Reuters· 4 mins ago
Lexaria Bioscience: Dehydratech-Processed Rybelsus Evidenced Trend Toward Higher Overall Absorption Vs Rybelsus Not Processed With Dehydratech

$Lexaria Bioscience (LEXX.US)$ nice

Lexaria Bioscience Corp. Reports Positive Interim Body Weight Results from Diabetes Animal Study.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced interim results from the first four weeks of dosing in its ongoing diabetes animal study, WEIGHT-A24-1 (the "Study"). $Lexaria Bioscience (LEXX.US)$
https://stockregion.app/p/bioscience-company-reports-positive-6c7

$Lexaria Bioscience (LEXX.US)$
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Lexaria Bioscience Corp. (Nasdaq: LEXX) reports positive interim results from its diabetes animal study WEIGHT-A24-1. After 28 days of dosing, DehydraTECH-processed drug therapies showed decreased body weight gain or weight reduction. Key findings include:
1. DehydraTECH-CBD formulation 3 and DehydraTECH-liraglutide produced the largest weight loss: -1.50% and -1.58% respectively.
2. De...